These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

Q4 2024 Earnings Call Transcript March 12, 2025 Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $0.06, ...

Q4 2024 Earnings Call Transcript March 11, 2025 MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.1004, ...

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.

PFA utilizes electrical pulses to induce non-thermal irreversible electroporation to cause cell death, while VHPSD utilizes radiofrequency energy and delivers 90W for up to 4 seconds with constant ...